HK Stock Market Move | ZHAOKE OPHTH-B(06622) surged over 7% and reached an agreement with Indonesian pharmaceutical company PT Ferron to distribute presbyopia medicine.

ZHAOKE OPHTH-B(06622) surged over 7%, reaching 7.64% at the time of writing, trading at HK$3.38 with a turnover of HK$2.3893 million. On the news front, on the evening of November 6, Zhaoke Ophthalmology announced that the company has signed a distribution and supply agreement with PT Ferron Par Pharmaceuticals, a leading pharmaceutical company in Indonesia, for one of the company's core products, the innovative drug BRIMOCHOL PF used to treat presbyopia. The drug is authorized for introduction by Tenpoint Therapeutics, Ltd. According to the agreement, Zhaoke Ophthalmology grants PT Ferron the exclusive rights to import, promote, distribute, market, and sell the product in Indonesia. Zhaoke Ophthalmology will receive an upfront payment and additional milestone payments based on certain achievements. In addition, Tenpoint Therapeutics, the developer of BRIMOCHOL PF, announced in June 2025 that the U.S. Food and Drug Administration has accepted the new drug application for the drug and has set the Prescription Drug User Fee Act (PDUFA) date for January 28, 2026.